Codiak BioSciences, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Codiak BioSciences, Inc.
New York biotech is partnering with researchers at Columbia, Kansas State and Southern Research to address the pandemic.
Merck pays undisclosed upfront fees and promises up to $500m for milestones under licensing and collaboration agreement. Meanwhile, Tetraphase and Xerava are being acquired by La Jolla, after previous bids by Melinta and AcelRx.
Emerging Company Profile: South Korea-based ILIAS Biologics aims to establish an exosome therapeutic development pathway using its platform technology EXPLOR, which is said to enable loading large therapeutic proteins into exosomes and stably deliver encapsulated cargo proteins to target cells.
Public Company Edition: Jefferies report notes robust IPO market, but SVB Leerink predicts a financing slowdown. Also, Mirati raises cash for KRAS programs after Amgen's ASCO data and a strategic shift results in job cuts at ImmunoGen.
- Drug Delivery
- Antisense, Oligonucleotides
- Gene Therapy, Cell Therapy